Siegelin et al. evaluated the in vitro and in vivo efficacy of sorafenib, a multikinase inhibitor, on glioblastoma cells and found that treatment of patient-derived glioblastoma cells with low-concentration sorafenib significantly inhibited cell proliferation and STAT3 phosphorylation and induced apoptosis and autophagy, resulting in significant inhibition of intracranial glioma growth (Siegelin et al., 2010). The gene discussed is STAT3; the disease is glioblastoma.